Disclosed are 2-naphthoyl-guanidine derivatives as represented by the general formula (I), wherein R1, is a naphthalene ring, X is hydrogen； n is 1, 2, 3 or 4； and Q is independently cycloalkyl, thienyl, furyl, pyrazolyl, alkyl-substituted pyrazolyl, pyridyl, alkoxy-substituted pyridyl, phenyl, which may be substituted with an alkylsulphonamide, halogen or acetylamino group. Of particular importance are the compounds 5-thiophen-3-yl-2-naphthoyIguanidine, 5-(1-methyIpyrazol-4-yl)-2-naphthoylguanidine, 6-(3-thienyl)-2-napthoyl-guanidine, 5-phenyl-2-napthoyl-guanidine, 5-(thien-2-yl)-2-napthoyl-guanidine, 5-(1,3,5-trimethyIpyrazol-4-yl)-2-napthoyl-guanidine, 5-(1-isobutyl-1H-pyrazol-4-yl)-2-napthoyl-guanidine, 5-(3-furyl)-2-napthoyI-guanidine, 5-cyclopropyl-2-napthoyl-guanidine, 6-(1-methylpyrazol-4-yl)-2-napthoyl-guanidinium acetate, 5-(2,6-dimethoxypryridin-3-yl)-2-napthoyI-guanidine, 5-(2-chlorophenyl)-2-napthoyl-guanidine, 5-(4-(acetylamino)phenyl)-2-napthoyl-guanidine, 5-(3-(acetylamino)phenyl)-2-napthoyl-guanidine and 5-(4-((methyIsulphonyI)amino)phenyl)-2-napthoyl-guanidine, or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition which comprising a compound as defined above, optionally in combination with one or more pharmaceutical acceptable carriers, adjuvants or antiviral agents for the therapeutic or prophylactic treatment of a subject exposed to or infected by a virus such as Hepatitis C virus (HCV), Human lmmunodeficiency Virus (HIV) or Dengue virus.Compuesto de fórmula I: en la que R1 es n es1, 2, 3 ó 4； Q se selecciona independientemente de cicloalquilo, tienilo, furilo, pirazolilo, pirazolilo sustituido, piridilo, piridilo sustituido, fenilo, fenilo sustituido y heterociclo； y X es hidrógeno, o una sal farmacéuticamente aceptable del mismo.
